Headlands Research, Inc. and its subsidiaries (“Headlands”, “we”, or “us”) knows that you value your privacy. We are a clinical trial site network conducting clinical trials for pharmaceutical companies. This Privacy Policy explains the information we collect through the websites available via www.Headlandsresearch.com and other Headlands managed websites or services that include an authorized link or reference to this Privacy Policy (collectively, the “Services”). By using the Headlands Services, you consent to the data practices described in this statement.
We collect the following categories of information when you access or use the Services, which may be considered personal information when maintained in identifiable form.
We may also collect information from other sources in accordance with applicable law. For example, we may collect information that you have authorized your health care provider to share with us. Information that is collected when you use the Services may be combined with other information collected from you or other sources.
We may aggregate or de-identify the information described above. Aggregated or de-identified data is not subject to this Privacy Policy.
We use and otherwise process each of the categories of information identified above for the following business purposes:
Headlands generally does not sell, rent or lease its customer lists to third parties. However, we may share your information with the following third parties:
When you use the Services, we and our third-party analytics and advertising partners may use cookies, pixel tags, and other similar technologies (collectively, “cookies”) to collect information about your browser and use of the Services. This helps us, for example, measure and understand how visitors interact with the online Services and our content, deliver customized content, and improve the Services. By using the Services, you consent to our use of cookies and similar technologies. Please consult your browser settings and mobile settings for choices that may be available to you to limit cookies. Depending on your settings, you may not be able to take advantage of all of the features of the Services.
The following types of cookies are used on the Services:
You may be able to refuse or disable cookies by adjusting your web browser settings. Some browsers have options that allow the visitor to control whether the browser will accept cookies, reject cookies, or notify the visitor each time a cookie is sent. Because each web browser is different, please consult the instructions provided by your web browser (typically in the “help” section). Please note that you may need to take additional steps to refuse or disable Local Shared Objects and similar technologies. For example, Local Shared Objects can be controlled through the instructions on Adobe’s Setting Manager page. If you choose to refuse, disable, or delete these technologies, some of the functionality of the Services may no longer be available to you and any differences in service are related to the data. Deleting cookies may in some cases cancel the opt out selection in your browser.
Some of our third-party partners are members of the Network Advertising Initiative, which offers a single location to opt out of ad targeting from member companies. To learn more, please click here or here. For additional information on how Google processes your information and what choices you may have, visit their site here.
Do-Not-Track Signals and Similar Mechanisms. Some mobile and web browsers transmit "do-not-track" signals. Because of differences in how web browsers incorporate and activate this feature, it is not always clear whether users intend for these signals to be transmitted, or whether they even are aware of them. We currently do not take action in response to these signals.
The Services may contain links to other third-party websites, which may be able to collect information about you. Please be aware that we are not responsible for the content or privacy practices of such third-party websites. We encourage our users to be aware when they leave our Services and to read the privacy statements of any other website that collects personally identifiable information.
You may be entitled, in accordance with applicable law, to request access to or deletion of your information or more information about our information practices. To submit a data access or data deletion request, please contact us at Privacy@headlandsresearch.com.
Please note that you must verify your identity and request before Headlands will process your request. You may be required to provide email confirmation or other information in order for us to verify your identity. We will not discriminate against you for exercising your rights and choices, although some of the functionality and features available on the Services may change or no longer be available to you.
Under certain circumstances, you may designate an authorized agent to make a request on your behalf. In order to designate an authorized agent to make a request on your behalf, you must provide a valid power of attorney, your valid government issued identification, and the authorized agent’s valid government issued identification to allow Headlands to verify that the agent is authorized to make the request on your behalf.
Headlands does not knowingly collect personally identifiable information from children under the age of thirteen through its online Services. If we learn that a child has provided us with personal information, we will delete it or otherwise comply with applicable law.
From time to time, Headlands may contact you via email for the purpose of providing announcements, promotional offers, alerts, confirmations, surveys, and/or other general communication. In order to improve our Services, we may receive a notification when you open an email from Headlands or click on a link therein.
You may also opt into marketing or promotional communications through the Services. If you would like to stop receiving marketing or promotional communications via email from Headlands, you may opt out of such communications by clicking an unsubscribe link that is included in emails sent when we use a third party email service, or replying to the email requesting to be removed from our list.
We take reasonable steps to protect your information from unauthorized access. You should keep in mind, however, that no internet transmission is ever 100% secure or error free. In particular, email sent to or from this web site or online resource may not be secure, and you should therefore take special care in deciding what information you send to us via email.
Headlands is a U.S. company, and your communication with us may result in the transfer of information across international boundaries, including to U.S. law enforcement. By using this site, you consent to the collection, storage, and processing of your information outside your jurisdiction of residence.
Headlands reserves the right to change this Privacy Policy from time to time. We will notify you about significant changes in the way we treat personal information by placing a prominent notice on our website, and/or by updating any privacy information on this page. Your continued use of the Services after such modifications will constitute your: (a) acknowledgment of the modified Privacy Policy; and (b) agreement to abide and be bound by that Policy.
Headlands welcomes your questions or comments regarding this Privacy Policy. If you believe that Headlands has not adhered to this Privacy Policy, please contact Headlands at:
Headlands Research, Inc.
130 JFK Dr., Suite 203
Lake Worth, FL 33462
Email Address:
privacy@headlandsresearch.com
Effective as of December 15, 2020
A board-certified psychiatrist, Dr. Herts has been involved in clinical trials of investigational treatments for CNS disorders including MDD, treatmentresistant depression, OCD, bipolar disorder, ADD/ADHD, and migraines.
Dr. Herts is a clinical research investigator at Pharmasite Research. Additionally, she is a clinical psychiatrist in private practice in Baltimore, MD and a psychiatrist at Sheppard and Enoch Pratt Hospital. As a research investigator, Dr. Herts has worked on numerous clinical trials of investigational treatments for central nervous system disorders, including major depression, treatment-resistant depression, bipolar disorder, ADD/ADHD, obsessive-compulsive disorder (OCD), and migraine headache.
Dr. Herts earned her medical degree from the West Virginia School of Osteopathic Medicine and completed her residency in Psychiatry at the University of Maryland and Sheppard and Enoch Pratt Hospital. She is board certified by the American Board of Psychiatry. She specializes in the treatment and research of depression, anxiety, bipolar disorder, addiction, PTSD, OCD, ADHD, and personality disorders in the adult population. Dr. Herts provides a collaborative, comprehensive, and holistic approach and values continuity of care with other providers and her patients’ loved ones when appropriate and permitted.
A board-certified psychiatrist, Dr. Dubin has been involved in clinical trials of investigational treatments for MDD, treatment-resistant depression, OCD, PTSD, and more.
Dr. Dubin is a clinical research investigator at Pharmasite Research and a solo practitioner in her private practice in Baltimore, MD. She is also a Coordinator of Psychiatric Education and Training for the Behavioral Health Administration of the state of Maryland and an Associate Training Director in the University of Maryland/Sheppard Pratt Psychiatry Residency Training Program. Board certified in psychiatry and neurology, Dr. Dubin’s clinical interests include mood and anxiety disorders, and her research experience covers obsessive-compulsive disorder (OCD), major depressive disorder (MDD), treatment-resistant depression, and PTSD.
Dr. Dubin earned her medical degree and completed her residency at the University of Maryland School of Medicine, and she completed an extramural fellowship in cognitive therapy at the Beck Institute for Cognitive Therapy. She has held academic teaching positions in psychiatry at the University of Maryland School of Medicine and Johns Hopkins Medicine. Dr. Dubin is also a member of the Maryland Psychiatric Society, Distinguished Fellow of the American Psychiatric Association, and Founding Fellow of the Academy of Cognitive Therapy.
Dr. Dubin contributes her time to her community as well as other medical professionals. During her time as Associate Training Director of the Adult Outpatient Psychiatry Clinic, she developed an acute crisis intervention program to provide urgent services to medical students in crisis as well as the “Residents’ PA Clinic” that continues to allow residents to see additional patient populations they would not normally encounter in their clinical site. During the COVID-19 pandemic, she volunteered for the Physician Support Line, a national program to support physicians. She has also served on the boards of several local non-profit organizations that support a range of causes, from women experiencing infertility to violence prevention. She is proficient in Hebrew and has a working knowledge of Spanish.
Dr. Hnoosh’s experience spans primary care practice, clinical research, and entrepreneurship, and she delivers the highest quality care to her patients in all settings.
Dr. Hnoosh is Principal Investigator at Pharmasite Research, a primary care physician in the Ambulatory and Emergency Care Clinical Center (AECCC) and women’s health clinic at the Baltimore VA Medical Center, and a primary care physician offering telemedicine services for AkosMD. She is also CEO, owner, and founder of Celesticare, LL, a special needs and elderly care medical equipment retailer that supplies directly to customers as well as to businesses. Dr. Hnoosh’s research experience includes Alzheimer’s disease and other dementias, migraine, diabetes, endometrial cancer, and pancreatic cancer.
Dr. Hnoosh earned her medical degrees at the University of Baghdad School of Medicine in Iraq and Xavier University School of Medicine in Aruba. She completed her residency in internal medicine at Medstar Health Internal Medicine and a fellowship in geriatric medicine at the University of Maryland Medical Center, both in Baltimore, MD. She is currently an Adjunct Assistant Professor in the Department of Medicine at the University of Maryland School of Medicine and mentors fellows in geriatric medicine and nurse practitioners at Baltimore VA Hospital.
Bio Coming Soon!
Alan Jonas, M.D is a clinical research investigator and co-owner of Pharmasite Research, Inc., a clinical trials company dedicated to industry sponsored neuroscience outpatient research. Pharmasite Research, Inc. has been in existence for 11 years and is widely respected for quality clinical research. Dr Jonas has functioned as the principal investigator or sub investigator in over 80 clinical trials in areas including depression, bipolar disorders, anxiety disorders, ADD in adults and children, geriatric depression, dementia of the Alzheimer’s type and vascular type, sleep disorders, fibromyalgia, sexual dysfunction associated with antidepressant treatment, and schizophrenia. He is the author or co author of several research papers resulting from these studies.
In addition Dr. Jonas is a board certified adult and geriatric psychiatrist and has been active in a mental health oriented group private practice for the past 21 years. His areas of expertise include neuropsychiatry, psychopharmacology, geriatric psychiatry, mood disorders and adult ADD.
Dr. Jonas serves on the faculty or speakers bureau of seven pharmaceutical companies, including the national speakers bureau of Wyeth Pharmaceuticals.
He has given over 300 lectures and presentations and is invited and actively travels throughout the United States presenting psychopharmacologic industry sponsored lectures and case presentations and non industry CME lectures as well as participating in advisory boards.
Robert B. Lehman, M.D is practice director of Psychiatric Consultants, an outpatient psychiatric practice in Baltimore Maryland. He is also a partner and clinical research investigator at Pharmasite Research, and a psychiatrist at Sinai Hospital of Baltimore. As a principal investigator, he has examined the efficacy and safety profiles of various treatment options for a broad range of mental illnesses, including generalized anxiety disorder, panic disorder, social anxiety disorder, major depressive disorder, treatment resistant depression, obsessive-compulsive disorder, and schizophrenia, bipolar disorder, ADD/ADHD, child and adolescent depression and bipolar disorder, primary insomnia, co-morbid insomnia, Alzheimer’s Disease, and cognition studies.
Dr. Lehman is board certified by the American Board of Psychiatry and Neurology and is an active member of the America Psychiatric Association, the Medical and Chirurgical Society of Maryland, the Baltimore County Medical Association, and the Maryland Psychiatric Society. He is a Fellow of the American Psychiatric Association. He is past also Chairman of Education the P’TACH School in Baltimore, Maryland.
Dr. Lehman has served as a consultant in the Traumatic Brain Injury Unit at Sinai Hospital of Baltimore. He is also a clinical instructor in the department of psychiatry at the University of Maryland School of Medicine.
During his career, Dr. Lehman has authored and co-authored several scientific reports that have appeared in many leading journals, including Psychiatric Times, The Journal of Psychiatry and Neuroscience, CNS Spectrums, and Primary Psychiatry and Pediatrics. He has presented posters at Institute for Psychiatric Services Annual Meeting, NCDEU, and the US Psychiatric Congress.
Dr. Lehman earned his medical degree from the University of Maryland School of Medicine. He also completed his residency in Psychiatry and a fellowship in Child Psychiatry at Sheppard and Enoch Pratt Hospital in Towson, Maryland.
"*" indicates required fields